Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of iminostilbene in prevention and treatment of cerebral ischemia-reperfusion injury

A technology for cerebral ischemia-reperfusion and reperfusion injury, which is applied in cardiovascular system diseases, active ingredients of heterocyclic compounds, drug combinations, etc.

Pending Publication Date: 2020-04-03
INST OF MEDICINAL PLANT DEV CHINESE ACADEMY OF MEDICAL SCI
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There is no report on its use in the prevention and treatment of cardiac and cerebral ischemia-reperfusion injury

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of iminostilbene in prevention and treatment of cerebral ischemia-reperfusion injury
  • Application of iminostilbene in prevention and treatment of cerebral ischemia-reperfusion injury
  • Application of iminostilbene in prevention and treatment of cerebral ischemia-reperfusion injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Example 1 Detection of myocardial infarct size in rats with myocardial ischemia-reperfusion injury by ISB

[0033] Animals are randomly divided into 5 groups: 10 in every group, including: normal group, model group, ISB low-dose group (0.625mg / kg), ISB high-dose group (1.25mg / kg), diltiazem hydrochloride tablet group (16mg / kg). Each dose group of ISB and the diltiazem hydrochloride tablet group were given intragastric administration for three consecutive days before operation. After 30 minutes of ischemia in experimental animals and 24 hours of reperfusion, the rats were anesthetized, and the heart was taken out by thoracotomy. The heart was rinsed in normal saline, placed at -80°C for 7 minutes, and taken out. Starting from the apex of the heart, the heart was cut transversely in the direction of the ligature. 5-7 thin slices after 1-2mm. Put it into 2% TTC solution, heat it in a water bath at 37°C for 12min, put it in neutral formalin for fixation, let it stand ove...

Embodiment 2

[0035] Example 2 The effect of ISB on the pathological changes of cardiac tissue in rats with myocardial ischemia-reperfusion injury

[0036] After the experiment was over, the hearts were removed from the thoracotomy, fixed in paraformaldehyde, sectioned in paraffin, and stained with HE.

[0037] The result is as figure 2 As shown, the morphology and structure of myocardial cells in the sham operation group were normal, the myocardial cell membrane was intact, the tissue space was normal, there was no inflammatory cell infiltration, and the arrangement of myocardial fibers was regular. In the model group, the interstitial space of myocardial cells was enlarged, edema occurred in the interval, neutrophil infiltration was obvious, the direction of myocardial fibers was unclear, myocardial fibers were broken in some areas, and endocardial necrosis existed. Compared with the model group, the intercellular space in the ISB group was reduced, and the infiltration of inflammatory ...

Embodiment 3

[0038] Example 3 Effect of ISB on cardiac function in rats with myocardial ischemia-reperfusion injury

[0039] After 7 days of reperfusion, the animals were anesthetized with isoflurane. The VisualSonics Vevo 770 high-resolution small animal ultrasound imaging system was used to evaluate the cardiac structure and function of the rats in each group. The main detection indicators were LVEF and LVFS.

[0040] Such as image 3 As shown, compared with the sham group, the EF and FS of the IR model group were significantly reduced, while the ISB could significantly increase the EF and FS and improve cardiac function.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of iminostilene in preparation of a drug for treating cardiovascular and cerebrovascular diseases, particularly cardiac and cerebral ischemia-reperfusion injury. Theiminostilene can reduce myocardial triose and inflammatory factors during ischemia-reperfusion and reduce cell apoptosis during ischemia-reperfusion.

Description

technical field [0001] The invention belongs to the field of cardiovascular and cerebrovascular diseases, and more specifically, the invention relates to the application of Iminostilbene in preventing and treating cardio-cerebral ischemia-reperfusion injury. Background technique [0002] With the aging of the society and the acceleration of urbanization, the unhealthy lifestyle of residents is popular, and the risk factors of cardiovascular and cerebrovascular diseases are generally exposed and become multiple diseases. Cardiovascular and cerebral ischemic diseases caused by thrombus, vascular rupture and other reasons are very common, and the treatment is generally based on antithrombotic decongestion therapy. After the ischemic myocardium and brain are restored to blood reperfusion, various aspects of damage will further aggravate, that is, ischemia-reperfusion injury, which has become a major obstacle in the treatment of ischemic diseases. The cause of reperfusion injury ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/55A61P9/00A61P9/10
CPCA61K31/55A61P9/00A61P9/10
Inventor 孙晓波孙桂波卢珊许旭东田瑜
Owner INST OF MEDICINAL PLANT DEV CHINESE ACADEMY OF MEDICAL SCI